Similarly, Acar et al. determined that lung cancer cells that harbour oncogenic mutant EGFR that acquire resistance to the EGFR inhibitor gefitinib develop collateral sensitivity to c-MET inhibitor capmetinib19. This evidence concerns the gene MET and lung carcinoma.